(Albany, US) DelveInsight has launched a new report on “Neurofibromatosis 2 Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s ” Neurofibromatosis 2 Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Neurofibromatosis 2 , historical and forecasted epidemiology as well as the Neurofibromatosis 2 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Neurofibromatosis type 2 Facts:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-market
Scope of the Report
Neurofibromatosis type 2 (NF2) is a rare genetic disorder characterized by the growth of non- cancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition.
Mutations in the NF2 gene cause neurofibromatosis type 2. The NF2 gene provides instructions for making a protein called merlin (also known as schwannomin). Merlin surrounds and insulate nerve cells (neurons) in the brain and spinal cord. Mutations in the NF2 gene lead to the production of a nonfunctional version of the merlin protein that cannot regulate the growth and division of cells.
The signs and symptoms of neurofibromatosis type 2 usually appear during adolescence or in a person’s early twenties, although they can begin at any age. The most frequent early symptoms of vestibular schwannomas are hearing loss, ringing in the ears (tinnitus), and problems with balance. Complications of tumor growth can include changes in vision, numbness or weakness in the arms or legs, and fluid buildup in the brain.
Some people with neurofibromatosis type 2 also develop clouding of the lens (cataracts) in one or both eyes, often beginning in childhood.
NF2 affects males and females equally.
Some of Neurofibromatosis type 2 Companies:
Neurofibromatosis type 2 Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Neurofibromatosis 2
3. Competitive Intelligence Analysis for Neurofibromatosis 2
4. Neurofibromatosis 2 : Market Overview at a Glance
5. Neurofibromatosis 2 : Disease Background and Overview
6. Patient Journey
7. Neurofibromatosis 2 Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Neurofibromatosis 2 Treatment
11. Marketed Products
12. Emerging Therapies
13. Neurofibromatosis 2 : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neurofibromatosis 2
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/neurofibromatosis-2-market